{"preliminary_commentary":{"by_channel":{"bluesky_thread":9,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06312670\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"NCT06312670","nct_id":"NCT06312670","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06312670. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"EPI-7386 at 600 mg twice daily orally with standard of care Enzalutamide at 160 mg, once daily, orally for 36 months of treatment (11 cycles).","label":"EPI-7386 + Enzalutamide","type":"EXPERIMENTAL"}],"collaborators":["ESSA Pharma Inc."],"completion_date":{"date":"2025-01-09","type":"ACTUAL"},"conditions":["Metastatic Hormone-sensitive Prostate Cancer (mHSPC)","Prostate Cancer","Prostate Adenocarcinoma"],"enrollment":{"count":13,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"EPI-7386","otherNames":[],"type":"DRUG"},{"name":"Enzalutamide","otherNames":[],"type":"DRUG"},{"name":"Androgen Deprivation Therapy (ADT)","otherNames":[],"type":"DRUG"}],"last_update":"2025-05-29","lead_sponsor":"Pedro Barata, MD, MSc","official_title":"Phase 2 Trial Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2025-01-09","type":"ACTUAL"},"primary_outcomes":[{"measure":"Biochemical response rate","timeFrame":"Post-intervention at Week 4"},{"measure":"PSA progesterone-free survival (PFS)","timeFrame":"Post-intervention at Week 4"},{"measure":"Radiographic PFS (rPFS)","timeFrame":"Post-intervention at Week 4"},{"measure":"ORR (confirmed)","timeFrame":"Post-intervention at Week 4"}],"references":[{"citation":"Jang A, Fowler P, Helminiak K, Kumar HLS, Pasucal J, Delong V, Zhong JY, Jindal T, Grier AL, Patel RR, Hislop M, Cesano A, Villaluna K, Younginger B, Wolff K, Richey K, Bray J, Garcia H, Adamowicz T, Reese A, Nizam A, Gupta S, Wee CE, Margevicius S, Fu P, Mendiratta P, Sheng IY, Brown JR, Garcia JA, Barata PC. EXTRA-PC: a phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-naive metastatic hormone-sensitive prostate cancer. Oncologist. 2026 Jan 17;31(2):oyaf434. doi: 10.1093/oncolo/oyaf434.","pmid":"41467749","type":"DERIVED"}],"start_date":{"date":"2024-05-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT06312670"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06312670"}